Sipai Health Technology (0314) H2 2024 earnings summary

Executive summary

• 2024 revenue fell 3.1% YoY to RMB4,565.4m; IFRS net loss widened 46.7% to RMB361.8m, while normalized net loss narrowed 11.8% to RMB127.1m.

• Strategy shifted toward scaling health insurance services and strengthening healthcare and pharmaceutical support networks; pharmacy and Hui Min Insurance restructuring is intended to improve efficiency and support a group-wide return to profit.

Financial highlights

• Gross profit decreased 6.8% to RMB386.4m and gross margin declined to 8.5% from 8.8%; operating loss narrowed 12.2% to RMB238.1m.

• IFRS loss for the year was RMB361.8m versus RMB246.7m in 2023; loss attributable to parent shareholders was RMB323.7m versus RMB255.8m.

• Basic and diluted loss per share was RMB0.51 versus RMB0.40; total comprehensive expense was RMB360.2m versus RMB231.9m.

• Selling and marketing expenses fell 4.8% to RMB278.4m, administrative expenses fell 6.8% to RMB324.0m, and R&D expenses fell 51.4% to RMB22.3m.

Outlook and guidance

• 2025 priorities include continuing pharmacy and Hui Min Insurance restructuring, completing the pharmaceutical supply-chain support network, and expanding commercial health insurance; the stated goal is an overall turnaround from loss to profit.

• Medium-to-long-term plans include integrated insurance and health management products, online/offline care, stronger medication services, data and AI applications, and deeper collaboration with insurers, healthcare providers and pharmaceutical companies.